Cover Image
Market Research Report
Product code

Highs and Lows of Stem Cell Therapies: Off - The-Shelf Solutions

Published: | BCC Research | 25 Pages | Delivery time: 1-2 business days


Back to Top
Highs and Lows of Stem Cell Therapies: Off - The-Shelf Solutions
Published: December 23, 2019
BCC Research
Content info: 25 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents

Report Highlights:

This report will review the current commercial and regulatory landscape for the stem cell therapies, and assesses the challenges and opportunities for developing autologous and allogenic “off the shelf” solutions to treat a broad range of diseases and injuries.

Report Includes:

  • An overview of recent advances in stem cell therapies and coverage of potential stem cells used for regenerative advanced therapies
  • Discussion on role of genomic and epigenomics manipulations in generating safe and effective treatment options
  • Identification of autologous and allogeneic cells and their usage in creating advanced therapy medical products (ATMPs)
  • Information on 3D cell culture and discussion on advances in gene editing and gene programming techniques such as CRIPSR/Cas9, TALEN, and ZINC fingers
  • Insights into commercial and regulatory landscape, and evaluation of challenges and opportunities for developing autologous and allogenic "off the shelf" solutions
Table of Contents
Product Code: BIO199A

Table of Contents

Chapter 1: Sources and Characteristics of Stem Cells

  • Introduction

Chapter 2: New Technologies Driving Stem Cell Development

  • Advances in Cell Culture
  • Advances in Isolation Technologies
  • Advances in Genome Manipulation

Chapter 3: Safety, Efficacy and Logistical Challenges

  • Toxicity-Related Treatment Issues
  • Logistical Challenges

Chapter 4: Off-the-Shelf Solutions

  • Expanding the Course of Stem Cells
  • More Precise Genomic Manipulation of Cells
  • Reduction in Cell-to-Cell Variation
  • Improved Shelf Life

Chapter 5: Companies and Technologies to Watch

  • Athersys Inc.
  • BrainStorm Cell Therapeutics Inc.
  • Caladrius Biosciences
  • Cellular Biomedicine Group Inc.
  • Fate Therapeutics Inc.
  • Gamida Cell Ltd.
  • International Stem Cell Corporation
  • Orgenesis Inc.
  • Pluristem Therapeutics Inc.
  • Sangamo Therapeutics Inc.
  • TheraCell Inc.
  • ThermoGenesis Holdings
  • Vericel Corporation
  • VistaGen Therapeutics Inc.
  • Zelluna Immunotherapy Inc.
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 6: References

List of Tables

  • Table 1: Stem Cell Sources
  • Table 2: Comparison of Stem Cells
  • Table 3: Stem Cell Types Versus Cell Properties
  • Table 4: Recent Advances in Genome Modulation Technologies
  • Table 5: FDA-Approved Cell-Based Therapies
  • Table 6: Acute and Delayed Adverse Events Associated with Proven and Unproven Stem Cell-Based Interventions
  • Table 7: Companies Leading the Field in Cell-Based Therapies

List of Figures

  • Figure 1: Stem Cell Sources
  • Figure 2: Two-Dimensional Versus Three-Dimensional Cell Culture
  • Figure 3: Schematic of Approaches Used for Three-Dimensional Stem Cell Culture
  • Figure 4: Patient Management Strategies to Decrease Side Effects Related with CAR-T Cell Therapy